NZ712341A - A crystalline form of an anxiolytic compound - Google Patents
A crystalline form of an anxiolytic compoundInfo
- Publication number
- NZ712341A NZ712341A NZ712341A NZ71234113A NZ712341A NZ 712341 A NZ712341 A NZ 712341A NZ 712341 A NZ712341 A NZ 712341A NZ 71234113 A NZ71234113 A NZ 71234113A NZ 712341 A NZ712341 A NZ 712341A
- Authority
- NZ
- New Zealand
- Prior art keywords
- crystalline form
- anxiolytic compound
- compound
- disease
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787436P | 2013-03-15 | 2013-03-15 | |
| AU2013204159A AU2013204159B2 (en) | 2013-03-15 | 2013-04-12 | A Crystalline Form of an Anxiolytic Compound |
| PCT/AU2013/000497 WO2014138772A1 (en) | 2013-03-15 | 2013-05-14 | A crystalline form of an anxiolytic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ712341A true NZ712341A (en) | 2019-07-26 |
Family
ID=51628585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ712341A NZ712341A (en) | 2013-03-15 | 2013-05-14 | A crystalline form of an anxiolytic compound |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9758516B2 (enExample) |
| EP (1) | EP2970290B1 (enExample) |
| JP (2) | JP2016510767A (enExample) |
| CN (2) | CN105377850A (enExample) |
| AU (2) | AU2013204159B2 (enExample) |
| CA (1) | CA2905573C (enExample) |
| MX (1) | MX369451B (enExample) |
| NZ (1) | NZ712341A (enExample) |
| WO (1) | WO2014138772A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105492440A (zh) * | 2013-03-15 | 2016-04-13 | 生态学有限公司 | 抗焦虑化合物的盐、共晶体和多晶型物 |
| WO2018102885A1 (en) * | 2016-12-09 | 2018-06-14 | Bionomics Limited | Modulators of nicotinic acetylcholine receptors and uses thereof |
| WO2019109150A1 (en) * | 2017-12-07 | 2019-06-13 | Bionomics Limited | Methods of treating agitation |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| MX2022003347A (es) * | 2019-09-23 | 2022-04-11 | Bionomics Ltd | Formulaciones terapeuticas y usos de las mismas. |
| AU2023201463A1 (en) * | 2023-03-08 | 2024-09-26 | Bionomics Limited | Method of treating social anxiety disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3688827T2 (de) * | 1985-10-25 | 1994-03-31 | Beecham Group Plc | Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel. |
| US20060004102A1 (en) * | 2004-05-07 | 2006-01-05 | Shlomit Wizel | Polymorphic forms of nateglinide |
| WO2008046135A1 (en) * | 2006-10-16 | 2008-04-24 | Bionomics Limited | Novel anxiolytic compounds |
| US20140051701A1 (en) * | 2011-03-02 | 2014-02-20 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| AU2012253237B2 (en) * | 2011-05-12 | 2015-09-24 | Bionomics Limited | Methods for preparing naphthyridines |
-
2013
- 2013-04-12 AU AU2013204159A patent/AU2013204159B2/en active Active
- 2013-05-14 MX MX2015013048A patent/MX369451B/es active IP Right Grant
- 2013-05-14 CA CA2905573A patent/CA2905573C/en active Active
- 2013-05-14 AU AU2013382559A patent/AU2013382559A1/en not_active Abandoned
- 2013-05-14 EP EP13878220.6A patent/EP2970290B1/en active Active
- 2013-05-14 NZ NZ712341A patent/NZ712341A/en unknown
- 2013-05-14 JP JP2015561822A patent/JP2016510767A/ja active Pending
- 2013-05-14 WO PCT/AU2013/000497 patent/WO2014138772A1/en not_active Ceased
- 2013-05-14 US US14/776,595 patent/US9758516B2/en active Active
- 2013-05-14 CN CN201380076497.9A patent/CN105377850A/zh active Pending
- 2013-07-12 CN CN201711041313.1A patent/CN107814799A/zh active Pending
-
2017
- 2017-06-29 US US15/638,107 patent/US20170305905A1/en not_active Abandoned
-
2018
- 2018-02-05 JP JP2018018526A patent/JP2018109011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018109011A (ja) | 2018-07-12 |
| EP2970290A4 (en) | 2016-08-31 |
| CN107814799A (zh) | 2018-03-20 |
| HK1220187A1 (en) | 2017-04-28 |
| US9758516B2 (en) | 2017-09-12 |
| EP2970290A1 (en) | 2016-01-20 |
| US20170305905A1 (en) | 2017-10-26 |
| WO2014138772A1 (en) | 2014-09-18 |
| AU2013204159A1 (en) | 2014-10-02 |
| EP2970290B1 (en) | 2020-07-22 |
| CN105377850A (zh) | 2016-03-02 |
| JP2016510767A (ja) | 2016-04-11 |
| US20160039810A1 (en) | 2016-02-11 |
| MX2015013048A (es) | 2016-09-07 |
| CA2905573A1 (en) | 2014-09-18 |
| AU2013204159B2 (en) | 2015-05-07 |
| MX369451B (es) | 2019-11-08 |
| CA2905573C (en) | 2021-03-02 |
| AU2013382559A1 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| MX2015012850A (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
| WO2014153100A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| WO2014153235A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
| CR20220368A (es) | Compuestos inhibidores de señalización de la trayectoria notch (divisional exp. n°2017-0598) | |
| MX2017001103A (es) | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. | |
| PH12017500451A1 (en) | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide | |
| PH12020550125A1 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| ZA201803476B (en) | Anti-cd22 antibody-maytansine conjugates and methods of use thereof | |
| NZ712341A (en) | A crystalline form of an anxiolytic compound | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX2015013059A (es) | Sales, co-cristales, y polimorfos de un compuesto ansiolitico. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAY 2021 BY CPA GLOBAL Effective date: 20200403 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAY 2022 BY CPA GLOBAL Effective date: 20210401 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAY 2023 BY CPA GLOBAL Effective date: 20220401 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAY 2024 BY CPA GLOBAL Effective date: 20230330 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAY 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240404 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAY 2026 BY DENNEMEYER AND CO. SARL Effective date: 20250505 |